ClinicalTrials.gg
TerminatedNCT00614666Updated Apr 16, 2025Results posted

Safety and PK of Nikkomycin Z for Coccidioides Pneumonia Treatment

A Phase 1/2 interventional study of nikkomycin Z and Placebo in Coccidioidomycosis, sponsored by University of Arizona. Terminated at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-04-16.

Sponsored by University of Arizona · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Recruitment challenges and lack of funding caused an early end to this study

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Coccidioidomycosis with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Coccidioidomycosis · United States.

Enrollment
10th of 11
6 · median 48
Started
2007
with 1 other
Phase 1/2
Only one
of the 16
Registered
3rd of 16
by date
Lead sponsor
3 of 16
University of Arizona

Among the 16 studies in Coccidioidomycosis with a site in United States, this one is the 10th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2007, is the only one in phase 1/2, and was the 3rd registered.

Coccidioidomycosis

21 studies on the registry are indexed under Coccidioidomycosis; 4 are open to participants now.

Browse Coccidioidomycosis studies →

Open to participants now

3 of the 16 studies in Coccidioidomycosis with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 2 Coccidioidomycosis studies recruiting now, 1 sets no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Coccidioidomycosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine if nikkomycin Z is safe when administered at different dose levels for 14 days. The study will also determine blood levels and urinary excretion of nikkomycin Z in relation to dose administered. Patients with mild forms of Valley Fever pneumonia will be eligible to participate and will be allocated to receive treatment with nikkomycin Z (various doses) or a placebo. A secondary goal of this study is to evaluate the effectiveness and dose response of nikkomycin Z in an exploratory analysis.

Read the detailed description

Every year there are 50,000 new U.S. cases of coccidioidomycosis (Valley Fever). The majority of these illnesses occur as a result of endemic exposure in Arizona and California. The benefits of antifungal therapy for uncomplicated disease are not currently established. Current therapies for serious and complicated forms of coccidioidomycosis are only partially effective and in themselves are unable to eradicate the fungus from sites of infection, commonly resulting in breakthrough infection and/or relapse. Nikkomycin Z is effective in the mouse model and results in improved microbiological response over fluconazole.

The goals of this study include: 1) Evaluating the safety and tolerance of nikkomycin Z following administration of multiple doses (50 mg Q 12 h to 750 mg Q 8 h) for two week and 2) Evaluating the pharmacokinetics of nikkomycin Z after single and multiple doses in relationship to dose. The study will include patients with uncomplicated Coccidioides pneumonia (mild illness) which will allow exploratory analysis of efficacy and dose response based on biomarkers.

03

Conditions studied

  • Coccidioidomycosis

Browse trials for

Keywords

  • coccidioidomycosis
  • Valley Fever
  • nikkomycin Z
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >= 18 years and \<= 50 years
  • Male or Female (if female, must have a negative pregnancy test and agree to use an acceptable method)
  • Able to understand study and give written
  • Have a respiratory illness with at least one of the following: Cough, chest pain dyspnea or tachypnea, sputum production, or fever/chills/night sweats
  • Have a new or suspected new pulmonary infiltrate on Chest X-ray
  • Have a positive coccidioidal serology by EIA or immunodiffusion

Exclusion criteria

Exclusion Criteria:

  • Patients under the age of 18 years or over 50 years
  • Patients with a prior history of confirmed coccidioidal infection
  • Laboratory diagnosis of another etiology for the inclusion-defining illness
  • Inability to comprehend study and provide
  • History of or current evidence of major organ disease
  • Concomitant use of prednisone and other not permitted
  • Concomitant therapy is not permitted
  • Concomitant antibacterial therapy is not permitted
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    A - First dose level (n=5)

    nikkomycin Z 50 mg BID x 14 days

    Drug: nikkomycin Z

  • Experimental
    B - Second Dose Level (n=10)

    nikkomycin Z nikkomycin Z 250 mg BID x 14 days

    Drug: nikkomycin Z

  • Experimental
    C - Third Dose Level (n=10)

    nikkomycin Z 500 mg BID x 14 days

    Drug: nikkomycin Z

  • Experimental
    D - Fourth Dose Level (n=5)

    nikkomycin Z 750 BID x 14 days

    Drug: nikkomycin Z

  • Placebo comparator
    Placebo

    placebo BID x 14 days

    Drug: Placebo

Interventions

  • Stage I: Multiple rising doses. Doses packaged on a unit dose basis in 50 and 250 mg capsules. Subjects take 1-3 capsules per dosing block for 14 days unless ADE or study withdrawal. Dose escalation unless a dose-limiting adverse effect is noted. Subjects assigned to BID dosing will receive 28 doses and subjects assigned to TID dosing will receive 42 doses. * 50 mg BID (n=4) vs placebo capsule BID (n=1) * 50 mg BID (n=4) vs 250 mg BID (n=4) vs Placebo capsule BID (n=2) * 250 mg BID (n=4) vs 500 mg BID (n=4) vs Placebo capsule BID (n=2) * 500 mg BID (n=4) vs Placebo capsule BID (n=1) At least 4 subjects complete lower dose before randomization includes next higher dose. Stage II will be a single dose level selected based on pharmacodynamics and safety from Stage I for 20 additional subjects using 4:1 randomization.

  • DrugPlacebo

    Placebo comparator

06

What researchers measure

Primary outcomes

  1. Concentration of Nikkomycin Z in the Blood Over Time (AUC)

    Time frame: 0, 0.25, 0.5, 0.75, 1.0, 1.5, 2 , 3, 4, 6, 8 and 12 h hours post-dose on Day 1 and Day 14

  2. Highest Concentration of Nikkomycin Z in the Blood (Cmax)

    Time frame: 0, 0.25, 0.5, 0.75, 1.0, 1.5, 2 , 3, 4, 6, 8 and 12 h hours post-dose on Day 1 and Day 14

07

Results

Posted Apr 16, 2025
Limitations and caveats
Early termination leading to small numbers of subjects analyzed

Participant flow

Participant flow — Overall Study
MilestoneA - First Dose LevelB - Second Dose LevelC - Third Dose LevelD - Fourth Dose LevelPlacebo
Started41001
Completed41001
Not completed00000

Outcome measures

PrimaryConcentration of Nikkomycin Z in the Blood Over Time (AUC)
Time frame:
0, 0.25, 0.5, 0.75, 1.0, 1.5, 2 , 3, 4, 6, 8 and 12 h hours post-dose on Day 1 and Day 14
Reported as:
Mean · mg*hr/L
Concentration of Nikkomycin Z in the Blood Over Time (AUC)
mg*hr/LA - First Dose Level (n=5)B - Second Dose Level (n=10)C - Third Dose Level (n=10)D - Fourth Dose Level (n=5)
Day 13.444 ± 0.71019.923 ± NA——
Day 143.900 ± 1.58324.045 ± NA——
PrimaryHighest Concentration of Nikkomycin Z in the Blood (Cmax)
Time frame:
0, 0.25, 0.5, 0.75, 1.0, 1.5, 2 , 3, 4, 6, 8 and 12 h hours post-dose on Day 1 and Day 14
Reported as:
Mean · mg/L
Highest Concentration of Nikkomycin Z in the Blood (Cmax)
mg/LA - First Dose Level (n=5)B - Second Dose Level (n=10)C - Third Dose Level (n=10)D - Fourth Dose Level (n=5)
Day 10.710 ± 0.1883.748 ± NA——
Day 140.811 ± 0.2484.275 ± NA——

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
A - First Dose Level (n=5)0/4 (0%)0/4 (0%)3/4 (75%)
B - Second Dose Level (n=10)0/1 (0%)0/1 (0%)1/1 (100%)
C - Third Dose Level (n=10)———
D - Fourth Dose Level (n=5)———
Placebo0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent other events
Most frequent other events
EventA - First Dose Level (n=5)B - Second Dose Level (n=10)C - Third Dose Level (n=10)D - Fourth Dose Level (n=5)Placebo
HeadacheGeneral disorders3/41/1——1/1
NauseaGastrointestinal disorders1/40/1——1/1
Left lung noduleRespiratory, thoracic and mediastinal disorders0/41/1——0/1
Right temple painGeneral disorders0/41/1——0/1
HypotensionVascular disorders1/40/1——0/1
Near syncopeGeneral disorders1/40/1——0/1
DiarrheaGastrointestinal disorders1/40/1——0/1
Dry mouthGeneral disorders1/40/1——0/1
InsomniaGeneral disorders1/40/1——0/1
Cataract surgeryEye disorders1/40/1——0/1

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)A - First Dose Level (n=5)B - Second Dose Level (n=10)C - Third Dose Level (n=10)D - Fourth Dose Level (n=5)PlaceboTotal
<=18 years000000
Between 18 and 65 years410016
>=65 years000000
Sex: Female, Male
Sex: Female, Male(Participants)A - First Dose Level (n=5)B - Second Dose Level (n=10)C - Third Dose Level (n=10)D - Fourth Dose Level (n=5)PlaceboTotal
Female100012
Male310004
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)A - First Dose Level (n=5)B - Second Dose Level (n=10)C - Third Dose Level (n=10)D - Fourth Dose Level (n=5)PlaceboTotal
Hispanic or Latino000000
Not Hispanic or Latino410016
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)A - First Dose Level (n=5)B - Second Dose Level (n=10)C - Third Dose Level (n=10)D - Fourth Dose Level (n=5)PlaceboTotal
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White410016
More than one race000000
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(participants)A - First Dose Level (n=5)B - Second Dose Level (n=10)C - Third Dose Level (n=10)D - Fourth Dose Level (n=5)PlaceboTotal
United States41——16
08

Study locations

1 site
  • Clinical & Translational Research Center - University of Arizona
    Tucson, Arizona 85721, United States
09

References and documents

Individual participant data

Plan to share: Yes — De-identified data may be shared for legitimate use to further nikkomycin Z development.

Supporting information: Study protocol, Informed consent form

Time frame: Study was terminated due to poor enrollment. Study report was not generated beyond safety data.

Access criteria: Contact Valley fever Solutions - current license for development.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2025, 15 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2008
First posted
Feb 13, 2008
Start
Sep 2007
Primary completionActual
Sep 2009
CompletionActual
Sep 2009
Results first posted
Apr 16, 2025
Last update
Apr 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00614666
Collaborators
FDA Office of Orphan Products Development
Responsible party
Sponsor
First posted
Feb 13, 2008
Start date
Sep 2007
Primary completion
Sep 2009
Completion
Sep 2009
Results posted
Apr 16, 2025
Last update
Apr 16, 2025

Study contacts

David E Nix, Pharm D
principal investigator · University of Arizona

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nikkomycin

Start the discussion